LD-2 disclosure · 2nd Quarter - Report
ABBVIE INC.
via ABBVIE, INC.
Client
- Name
- ABBVIE INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- ABBVIE, INC.
- Description
- Biopharmaceutical company
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesCopyright/Patent/Trademark
H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
LobbyistsSTEPHEN SCANGO · DANIEL BACHNER · DORCAS ADEKUNLE · CRYSTAL RILEY
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act H.R. 19, Lower Costs, More Cures Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 & 2023; Notice Requirement for Non-Federal Governmental Plans proposed rule Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program
LobbyistsSTEPHEN SCANGO · DANIEL BACHNER · DORCAS ADEKUNLE · CRYSTAL RILEY
TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office
Medicare/Medicaid